Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson Sells 1,000 Shares

Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson sold 1,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $235,000.00. Following the sale, the director now owns 12,722 shares in the company, valued at $2,989,670. This represents a 7.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Laboratory Co. of America Price Performance

Shares of LH stock opened at $232.12 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The company’s 50-day simple moving average is $234.59 and its two-hundred day simple moving average is $224.49. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $247.99. The company has a market capitalization of $19.41 billion, a P/E ratio of 44.90, a P/E/G ratio of 1.91 and a beta of 1.06.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.02. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. The firm had revenue of $3.28 billion for the quarter, compared to the consensus estimate of $3.26 billion. During the same period last year, the firm earned $3.38 earnings per share. The company’s quarterly revenue was up 7.4% on a year-over-year basis. As a group, equities analysts anticipate that Laboratory Co. of America Holdings will post 14.52 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.24%. Laboratory Co. of America’s dividend payout ratio is presently 55.71%.

Hedge Funds Weigh In On Laboratory Co. of America

Hedge funds and other institutional investors have recently modified their holdings of the business. SouthState Corp bought a new position in shares of Laboratory Co. of America during the third quarter valued at approximately $28,000. Horizon Bancorp Inc. IN purchased a new stake in Laboratory Co. of America during the third quarter valued at approximately $29,000. Fortitude Family Office LLC lifted its position in Laboratory Co. of America by 312.5% during the fourth quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 100 shares during the last quarter. Riverview Trust Co lifted its position in Laboratory Co. of America by 172.6% during the third quarter. Riverview Trust Co now owns 169 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 107 shares during the last quarter. Finally, Concord Wealth Partners lifted its position in Laboratory Co. of America by 43.3% during the third quarter. Concord Wealth Partners now owns 172 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 52 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Jefferies Financial Group restated a “buy” rating and set a $275.00 target price (up from $265.00) on shares of Laboratory Co. of America in a research report on Tuesday, December 10th. HSBC upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Wednesday, October 30th. Barclays upped their price target on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the company an “equal weight” rating in a report on Friday, October 25th. Morgan Stanley upped their price target on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Finally, Robert W. Baird upped their price target on shares of Laboratory Co. of America from $282.00 to $289.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $260.54.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.